90814-91-8

Basic information

• Product Name: 7-BROMO-2H-(1 4)-BENZOTHIAZIN-3(4H)-ONE&
• Synonyms: 7-Bromo-1,4-Benzothiazine-3-one;7-Bromo-3,4-dihydro-2H-1,4-benzothiazin-3-one;7-BroMo-2h-benzo[b][1,4]thiazin-3- one .;7-Bromo-2H-1,4-benzothiazin-3(4H)-one
• CAS NO: 90814-91-8
• Molecular Formula: C₈H₆BrNOS
• Molecular Weight: 244.10834
• Product Categories: Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Thiazines;ThiazinesHeterocyclic Building Blocks
• Mol File: 90814-91-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 210-214 °C(lit.)
• Boiling Point: 397.2 °C at 760 mmHg
• Flash Point: 194 °C
• Appearance: /
• Density: 1.689 g/cm³
• Vapor Pressure: 1.62E-06mmHg at 25°C
• Refractive Index: 1.657
• Solubility: soluble in Dimethylformamide
• CAS DataBase Reference: 7-BROMO-2H-(1 4)-BENZOTHIAZIN-3(4H)-ONE&(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMO-2H-(1 4)-BENZOTHIAZIN-3(4H)-ONE&(90814-91-8)
• EPA Substance Registry System: 7-BROMO-2H-(1 4)-BENZOTHIAZIN-3(4H)-ONE&(90814-91-8)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 90814-91-8(Hazardous Substances Data)

Usage

General Description

7-Bromo-2H-(1,4)-benzothiazin-3(4H)-one is a chemical compound that belongs to the benzothiazinone class of compounds. It contains a bromine atom and a benzothiazinone ring structure, which gives it unique chemical properties and potential applications. 7-BROMO-2H-(1 4)-BENZOTHIAZIN-3(4H)-ONE& is known for its antimicrobial and antibacterial properties, and it has been studied for its potential use as an antibiotic for the treatment of drug-resistant tuberculosis. Additionally, it has also been investigated for its potential as a drug for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. Its chemical structure and properties make it a valuable compound for research and potential pharmaceutical applications.

InChI:InChI=1/C8H6BrNOS/c9-5-1-2-6-7(3-5)12-4-8(11)10-6/h1-3H,4H2,(H,10,11)

Upstream product

• 5325-20-2 2H-1,4-benzothiazin-3-one 
• 105-36-2 ethyl bromoacetate 
• 23451-95-8 2-amino-5-bromobenzenethiol 
• 66416-72-6 4-bromo-2-iodoaniline 
• 2365-48-2 Methyl thioglycolate 
• 106-40-1 4-bromo-aniline 
• 105-39-5 chloroacetic acid ethyl ester 
• 73011-23-1 6-bromo-3H-1,2,3-benzodithiazole-2-oxide 

Downstream Products

• 912953-29-8 7-[4-(trifluoromethyl)phenyl]-2H-1,4-benzothiazin-3(4H)-one 
• 1208006-11-4 7-bromo-4-[2-(2,4-difluorophenyl)-2-hydroxy-3-[1,2,4]triazol-1-yl-propyl]-4H-benzo[1,4]thiazin-3-one 
• 1611467-38-9 7-{[3-(trifluoromethyl)phenyl]amino}-2H-benzo[b][1,4]thiazin-3(4H)-one 
• 1185265-03-5 2,2-Dimethyl-6-[7-(1-methyl-cyclohexanecarbonyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]-4H-benzo[1,4]oxazin-3-one 
• 305790-58-3 7-(3-nitro-phenyl)-4H-benzo[1,4]thiazin-3-one 

Relevant articles and documents

Facile synthesis of 1,4-benzothiazin-3-ones from Cu-catalyzed coupling of 2-iodoanilines and 2-mercaptoacetate

A novel synthesis of 1,4-benzothiazin-3-ones was developed from Cu-catalyzed coupling of readily available substituted 2-iodoanilines with 2-mercaptoacetate. The new method offers clear advantages over existing approaches for its one-step simple operation, wider reaction scope, and moderate to excellent isolated yields.

The bromination and nitration of some (2H)-1,4-benzoxazin-3(4H)-ones

Bromination of (2H)-1,4-benzoxazin-3-(4H)-one with bromine in glacial acetic acid gave firstly the 6-bromo and then the 6,7-dibromo compound whilst bromine in chloroform gave mainly the 7-bromo derivative. Bromination of the 6-chloro- and 6-methyl-(2H)-1,4-benzoxazin-3(4H)-ones and (2H)=1,4-benzothiazin-3(4H)-one gave the 7-bromo compounds. Nitration of (2H)-1,4-benzoxazin-3(4H)-one with a sulfuric acid : nitric acid mixture gave the 6-nitro and then 6,8-dinitro compound whilst nitrosation: nitration with sodium nitrite : fuming nitric acid gave mainly the 7-nitro compound. 6-Chloro-(2H)-1,4-benzoxazin-3(4H)-one gave 7-nitro compound.

Combination therapies using benzimidazolones

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R6are independently selected from H or optionally substituted C1to C6alkyl, C2to C6alkenyl, C2to C6alkynyl, C3to C8cycloalkyl, substituted C3to C8cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4and R5to from a 5 to 7 membered ring; R1is selected from H, OH, NH2, C1to C6alkyl, substituted C1to C6alkyl, C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, substituted alkynyl, —COH, or optionally substituted —CO(C1to C3alkyl), —CO(aryl), —CO(C1to C3alkoxy), or —CO(C1to C3aminoalkyl) groups; R2is selected from H, halogen, CN, NO2, or optionally substituted C1to C6alkyl C1to C6alkoxy, or C1to C6aminoalkyl groups; R3is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromnatic ring containing 1 or 2 substituents; or a pharmaceutically acceptable salt thereof, in combination with a progestational agent, an estrogen, or both or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. These combinations may also be used to in methods of contraception, to stimulate food intake or for minimization of side effects or cyclic menstrual bleeding.